s

This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Inhibitor of apoptosis (IAP); toll-like receptor 3 (TLR3); TLR9

In vitro and mouse studies suggest combining IAP inhibitors with oncolytic viruses or TLR agonists could help treat cancer. In human and mouse cancer cell lines, an IAP antagonist plus an oncolytic virus, TLR3 agonist or TLR9 agonist decreased cell viability synergistically compared with any agent alone. In mice with mammary or xenograft colorectal tumors, the combination therapy decreased tumor growth and increased survival compared with any agent alone. Ongoing work includes discussing plans with undisclosed partners for a Phase I trial of an IAP inhibitor and an oncolytic virus in patients with cancer.
At least six companies have IAP inhibitors in Phase II or earlier development to treat cancer.

SciBX 7(6); doi:10.1038/scibx.2014.168
Published online Feb. 13, 2014

Patent application filed by Children's Hospital of Eastern Ontario; licensing status undisclosed

Beug, S.T. et al. Nat. Biotechnol.; published online Jan. 26, 2014;
doi:10.1038/nbt.2806
Contact: Robert G. Korneluk, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
e-mail:
bob@arc.cheo.ca